Qlaris Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-11-17.
Qlaris Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 17, 2025. The filing reports $5.64M sold. Its industry group is Biotechnology. It names Thurein Htoo (Executive Officer, Director), Andrew Danielson (Director), Adrienne Graves (Director) (SEC Form D, November 17, 2025).
Is this your company?
Sell to companies like Qlaris Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-17 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Qlaris Bio, Inc.
Free to see. No signup.
More on the people and the money behind Qlaris Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in November 2025, largest first.
Get an email when Qlaris Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Qlaris Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Qlaris Bio, Inc. →Get the full cited report on Qlaris Bio, Inc.
What the filing shows about Qlaris Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Qlaris Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Qlaris Bio, Inc.'s address as 770 Legacy Place, 2nd Floor, Dedham, MA 02026.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Qlaris Bio, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Qlaris Bio, Inc. is a registered filer with the SEC (CIK 1786717) and has filed since 2024-04-22. 3 filings are on record, the latest on 2026-06-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Qlaris Bio, Inc.'s Form D of 2025-11-17 names Thurein Htoo, Andrew Danielson, Adrienne Graves and 3 more as its officers, directors or promoters.
Its new offerings report $33.62M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $5.64M, on the same scale — one filing against the whole group's total, so it sits low by construction.
No amounts other than ordinary course employment compensation is being paid to officers and directors.
Thurein Htoo is named as Executive Officer and Director on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
Andrew Danielson is named as Director on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
Adrienne Graves is named as Director on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
Ronald Hunt is named as Director on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
Wende Hutton is named as Director on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
Barbara Wirostko is named as Executive Officer on the Form D that Qlaris Bio, Inc. filed with the SEC on 17 November 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-11-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Qlaris Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Qlaris Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Qlaris Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Qlaris Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Qlaris Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Qlaris Bio, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/qlaris-bio-inc-form-d-25000001